- Pazopanib (GW-786034)
- AP26113
| BLU9931FGFR4 inhibitor,potent and irreversible |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.85%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Kinase experiment [1]: | |
FGFR1-4 biochemical assays | FGFR kinase inhibition assays were performed at KM for ATP. Picomolar to low nanomolar concentrations of FGFR proteins were incubated in 1 × Kinase Reaction Buffer with 1 μM of CSKtide and 50 to 250 of μM ATP at 25 °C for 90 mins in the presence or absence of a dosed concentration series of inhibitor. All reactions were terminated by the addition of Stop Buffer, and plates were read on a Caliper EZReader2. IC50 values were fit with a four-parameter log[Inhibitor] versus response model with floating Hill Slope. |
| Cell experiment [1]: | |
Cell lines | MDA-MB-453, DMS114 and Hep 3B cells |
Preparation method | This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
Reacting condition | 0.3 ~ 300 nM; 1 hr |
Applications | In MDA-MB-453 cells, BLU9931 dose-dependently and effectively reduced phosphorylation of FGFR4 signaling pathway components, including FRS2, MAPK and AKT. In DMS114 cells, BLU9931 exhibited minimal reduction of phosphorylation in all FGFR1 signaling pathway components. In Hep 3B cells, BLU9931 also potently inhibited phosphorylation of the FGFR4 pathway components (except pAKT). |
| Animal experiment [1]: | |
Animal models | Hep 3B tumor-bearing mice |
Dosage form | 10, 30 and 100 mg/kg; p.o.; b.i.d., for 21 days |
Applications | BLU9931 dose-dependently inhibited the growth of Hep 3B tumors. At the dose of 100 mg/kg, BLU9931 resulted in tumor regression. Moreover, 2 of the 9 mice showed no signs of tumor 30 days after cessation of treatment. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N, Shutes A, Winter C, Lengauer C, Kohl NE, Guzi T. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discov. 2015 Apr;5(4):424-37. | |
BLU9931 Dilution Calculator
calculate
BLU9931 Molarity Calculator
calculate
| Cas No. | 1538604-68-0 | SDF | Download SDF |
| Chemical Name | N-(2-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)-3-methylphenyl)acrylamide | ||
| Canonical SMILES | ClC1=C(C2=CC(C=NC(NC(C(NC(C=C)=O)=CC=C3)=C3C)=N4)=C4C=C2)C(Cl)=C(OC)C=C1OC | ||
| Formula | C26H22Cl2N4O3 | M.Wt | 509.38 |
| Solubility | ≥50.9mg/mL in DMSO | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
BLU9931 is a potent and irreversible inhibitor of FGFR4. BLU9931 potently inhibited FGFR4 activity (IC50 = 3 nmol/L), but weakly inhibited FGFR1 (IC50 = 591 nmol/L), FGFR2 (IC50 = 493 nmol/L), and FGFR3 (IC50 = 150 nmol/L) activity. Fibroblast growth factor receptor 4 (FGFR4) is the receptor of fibroblast growth factor 19 (FGF19), which is a tightly controlled hormone that regulates bile acid synthesis and hepatocyte proliferation in the normal liver. FGFR4 acts as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 signaling pathway. BLU9931 is highly selective for FGFR4 versus other FGFR family members and all other kinases. BLU9931 binds within the ATP-binding pocket of FGFR4, forming a covalent bond with Cys552. The anilino-quinazoline core of BLU9931 makes a bidentate hydrogen-bonding interaction with the hinge residue (Ala553) of FGFR4, whereas the dichlorodimethoxyphenyl group occupies the hydrophobic pocket, providing FGFR-family selectivity. BLU9931 displayed significant binding to only two of the 398 wild-type kinases, FGFR4 (99.7% inhibition relative to DMSO control; Kd = 6 nmol/L) and CSF1R (90.1% inhibition relative to DMSO control; Kd = 2716 nmol/L) by KINOMEscan method. [2]BLU9931 shows remarkable antitumor activity in mice bearing an HCC tumor xenograft that overexpresses FGF19 due to amplification as well as a liver tumor xenograft that overexpresses FGF19 mRNA but lacks FGF19 amplification.References:[1]. Hagel M, Miduturu C, Sheets M et al.First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discov. 2015 Mar 16. [Epub ahead of print][2]. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
看有关产前诊断的一个资料，提到：“凡是酶活性能在成纤维细胞中表达均可用绒毛或羊水细胞的酶活性测定进行产前诊断，如溶酶体贮积症。”
不太理解，为什么成纤维细胞中表达的酶就能在绒毛或羊水细胞中测出来呢？绒毛的细胞跟成纤维细胞没什么直接关系吧？或者是因为成纤维细胞脱落到羊水中，破裂，然后就可以检测了？
求各位解答，谢谢。
如癌症的CA抗原系列、用于测胆汁酸、尿酸之类的酶。
转换酶中的一类。催化氨基酸和a-氧代酸（a-酮酸
)或醛酸之间的氨基转换反应，生成与原来的a-氧代酸或醛酸相应的a-氨基酸或ω-
氨基酸，原来氨基酸转变成相应的氧代酸。转氨酶催化的反应都是可逆的。转氨酶可按底物的不同分成3大类。L-a-氨基酸（酮酸转氨酶） 、ω-
氨基酸（酮酸转氨酶）和D-氨基酸转氨酶。转氨酶的辅基是磷酸吡哆醛或磷酸吡哆胺，两者在转氨基反应中可互相变换。
转氨酶参与氨基酸的分解和合成。氨基酸转氨后生成的酮酸或醛酸可经氧化分解而供能，也可转变成糖类或脂肪酸。相反，酮酸或醛酸也可经转氨酶的作用而生成非必需氨基酸。某些氨基酸之间的互变也有转氨酶参与。在高等动物各组织中，活力最高的转氨酶是谷氨酸
： 草酰乙酸转氨酶（ GOT ）和谷氨酸：丙酮酸转氨酶（GPT）。
转氨酶是人体代谢过程中必不可少的“催化剂”，主要存在于肝细胞内。当肝细胞发生炎症、坏死、中毒等，造成肝细胞受损时，转氨酶便会释放到血液里，使血清转氨酶升高。
通常，体检中主要检查的转氨酶有丙氨酸转氨酶（ALT，俗称谷丙转氨酶）和天门冬氨酸转氨酶（AST，俗称谷草转氨酶），其中尤以前者（ALT）最为常用。1%的肝脏细胞损害，可以使血中ALT的浓度增加1倍。因此，ALT水平可以比较敏感地监测到肝脏是否受到损害。
~如果你认可我的回答，请及时点击【采纳为满意回答】按钮~ ~手机提问者在客户端右上角评价点“满意”即可。
~你的采纳是我前进的动力~~ ~如还有新的问题，请另外向我求助，答题不易，敬请谅解~~
